
NASDAQHealthcareBiotechnology
最新数据
US$103.32
−US$8.30 · -7.44%
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
前收盘价
US$103.32
−US$8.30 · -7.44%
盘中时间采用ET。市场数据可能有所延迟。
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
日内区间
当前US$103.32
52周区间
当前US$103.32
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
62
低估
情绪
45
多空交织
风险
55
风险偏高
动量
70
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
日内区间
当前US$103.32
52周区间
当前US$103.32
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 营收 | 4.59亿 USD | 3.77亿 USD | 3.13亿 USD | 2.45亿 USD | 2.04亿 USD |
| 销货成本 | 2.19亿 USD | 1.86亿 USD | 1.8亿 USD | 1.55亿 USD | 1.19亿 USD |
| 毛利 | 2.41亿 USD | 1.91亿 USD | 1.33亿 USD | 8972.9万 USD | 8423.5万 USD |
| 研究与开发 | 7183.6万 USD | 8028.5万 USD | 9085.2万 USD | 1.07亿 USD | 1.2亿 USD |
| 销售、一般及管理费用 | 3.01亿 USD | 2.47亿 USD | 2.18亿 USD | 1.9亿 USD | 2.13亿 USD |
| 营业费用 | 3.8亿 USD | 3.27亿 USD | 3.54亿 USD | 3.07亿 USD | 3.19亿 USD |
| 利息收入 | 880.3万 USD | 1136.4万 USD | 1534.4万 USD | 1436.5万 USD | 306.2万 USD |
| 利息支出 | — | — | 2.9万 USD | 5000 USD | 8万 USD |
| 折旧和摊销 | — | 2485.3万 USD | 3143.2万 USD | 2931万 USD | 1651.4万 USD |
| 营业利润 | −1.39亿 USD | −1.36亿 USD | −2.21亿 USD | −2.17亿 USD | −2.35亿 USD |
| 净利润 | −1.3亿 USD | −7767万 USD | −2.09亿 USD | −2.05亿 USD | −2.18亿 USD |
公司数据更新于 2026年11月22日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$144.91
上涨空间 40.25%报告持有此股票敞口的交易所交易基金。
ARK Innovation ETFARKK5.88亿3.28%61.23亿 USD0.75%US$64.22-6.83%
Vanguard Morningstar Total Stock Market ETFVTI2.54亿0.01%6893亿 USD0.03%US$340.02-3.52%
Vanguard Morningstar Small-Cap ETFVB2.27亿0.13%787亿 USD0.03%US$270.68-2.56%
iShares Russell 2000 ETFIWM1.84亿0.25%715.37亿 USD0.19%US$256.61-2.88%
ARK Genomic Revolution ETFARKG1.49亿8.57%22.11亿 USD0.75%US$38.00-5.64%
State Street SPDR S&P Biotech ETFXBI1.35亿1.40%96.36亿 USD0.35%US$140.18-2.73%
Vanguard Morningstar Small-Cap Growth ETFVBK1.27亿0.30%225亿 USD0.05%US$298.35-3.85%
Vanguard Extended Market ETFVXF1.15亿0.12%302亿 USD0.05%US$211.44-3.21%
ARK Innovation ETFARKK
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Morningstar Small-Cap ETFVB
iShares Russell 2000 ETFIWM
ARK Genomic Revolution ETFARKG
State Street SPDR S&P Biotech ETFXBI
Vanguard Morningstar Small-Cap Growth ETFVBK
Vanguard Extended Market ETFVXFAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。